Revance Therapeutics (RVNC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2018 | 12-2017 | 12-2016 | 12-2015 | 12-2014 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 73,256 | 282,896 | 63,502 | 201,650 | 171,107 |
| Marketable Securities | 102,556 | N/A | 122,026 | 50,688 | N/A |
| Receivables | 27,000 | 48 | N/A | N/A | N/A |
| TOTAL | $207,922 | $285,211 | $192,695 | $253,963 | $172,731 |
| Non-Current Assets | |||||
| PPE Net | 14,449 | 9,250 | 10,585 | 19,708 | 19,274 |
| Investments And Advances | 0 | 0 | 0 | 1,751 | 0 |
| Other Non-Current Assets | 3,977 | 1,238 | 1,080 | 400 | 464 |
| TOTAL | $18,426 | $10,488 | $11,665 | $21,859 | $19,738 |
| Total Assets | $226,348 | $295,699 | $204,360 | $275,822 | $192,469 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | 1,872 | 3,475 | 3,135 | 2,942 |
| Accounts payable and accrued liabilities | 8,434 | 6,805 | 3,754 | 2,657 | 3,149 |
| Accrued Expenses | 14,948 | 12,225 | 12,418 | 6,245 | 4,145 |
| TOTAL | $31,970 | $20,902 | $19,647 | $12,037 | $10,236 |
| Non-Current Liabilities | |||||
| Long Term Debt | N/A | N/A | 1,872 | 5,346 | 598 |
| Deferred Revenues | 8,588 | N/A | N/A | N/A | N/A |
| Other Non-Current Liabilities | 2,753 | 2,613 | 2,122 | 1,414 | 1,541 |
| TOTAL | $48,756 | $5,952 | $7,642 | $10,533 | $5,864 |
| Total Liabilities | $80,726 | $26,854 | $27,289 | $22,570 | $16,100 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 44,029 | 36,685 | 29,319 | 28,433 | 23,935 |
| Common Shares | 37 | 37 | 29 | 28 | 24 |
| Retained earnings | -684,775 | -542,167 | -421,543 | -332,273 | -258,797 |
| Other shareholders' equity | -8 | 0 | -45 | -40 | 0 |
| TOTAL | $145,622 | $268,845 | $177,071 | $253,252 | $176,369 |
| Total Liabilities And Equity | $226,348 | $295,699 | $204,360 | $275,822 | $192,469 |